Exclusive Summary

• - Macrocyclic, ionic GBCA with a favorable safety profile preferred by ACR/ESUR, making it a first-line contrast option across markets.
• - An estimated 42–63 million contrast-enhanced MRI doses are performed globally each year; 5–100 mL SKUs cover outpatient and high-throughput center needs.
• - US registration signals robust quality and compliance, enabling rapid distribution partnerships and market entry.
• - Pricing can be 20–40% below originators, with the 100 mL pack further reducing per-exam unit cost.
• - Macrocyclic agents hold >70% share in US/EU while linear agents are restricted; this product differentiates via safety and complete vial-size portfolio.